The p38 mitogen-activated protein kinase pathway-A potential target for intervention in infarction, hypertrophy, and heart failure

Michael S. Marber; Beth Rose; Yibin Wang

doi:10.1016/j.yjmcc.2010.10.021

The p38 mitogen-activated protein kinase pathway-A potential target for intervention in infarction, hypertrophy, and heart failure

Michael S. Marber, Beth Rose, Yibin Wang

Cardiovascular Sciences

University of California, Los Angeles

Research output: Contribution to journal › Literature review › peer-review

135 Citations (Scopus)

Abstract

The p38 mitogen-activated protein kinases (p38s) are stress-activated Ser/Thr kinases. Their activation has been associated with various pathological stressors in the heart. Activated p38 is implicated in a wide spectrum of cardiac pathologies, including hypertrophy, myocardial infarction, as well as systolic and diastolic heart failure. In this review, the specific contribution of different isoforms of p38 kinases to cardiac diseases as well as TAB-1-mediated non-canonical activation pathway are discussed as a rationale for inhibiting p38 activity to treat cardiac hypertrophy, ischemic injury, and heart failure. Finally, a summary of current clinical trials targeting p38 kinases in cardiovascular diseases is provided to highlight the potential promise as well as existing challenges of this therapeutic approach. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure." (C) 2010 Elsevier Ltd. All rights reserved.

Original language	English
Pages (from-to)	485 - 490
Number of pages	6
Journal	Journal of Molecular and Cellular Cardiology
Volume	51
Issue number	4
DOIs	https://doi.org/10.1016/j.yjmcc.2010.10.021
Publication status	Published - Oct 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.yjmcc.2010.10.021

Cite this

@article{4769df3b73184b9c8a24aaf80cec9779,

title = "The p38 mitogen-activated protein kinase pathway-A potential target for intervention in infarction, hypertrophy, and heart failure",

abstract = "The p38 mitogen-activated protein kinases (p38s) are stress-activated Ser/Thr kinases. Their activation has been associated with various pathological stressors in the heart. Activated p38 is implicated in a wide spectrum of cardiac pathologies, including hypertrophy, myocardial infarction, as well as systolic and diastolic heart failure. In this review, the specific contribution of different isoforms of p38 kinases to cardiac diseases as well as TAB-1-mediated non-canonical activation pathway are discussed as a rationale for inhibiting p38 activity to treat cardiac hypertrophy, ischemic injury, and heart failure. Finally, a summary of current clinical trials targeting p38 kinases in cardiovascular diseases is provided to highlight the potential promise as well as existing challenges of this therapeutic approach. This article is part of a special issue entitled {"}Key Signaling Molecules in Hypertrophy and Heart Failure.{"} (C) 2010 Elsevier Ltd. All rights reserved.",

author = "Marber, {Michael S.} and Beth Rose and Yibin Wang",

year = "2011",

month = oct,

doi = "10.1016/j.yjmcc.2010.10.021",

language = "English",

volume = "51",

pages = "485 -- 490",

journal = "Journal of Molecular and Cellular Cardiology",

issn = "1095-8584",

publisher = "ACADEMIC PRESS INC",

number = "4",

}

TY - JOUR

T1 - The p38 mitogen-activated protein kinase pathway-A potential target for intervention in infarction, hypertrophy, and heart failure

AU - Marber, Michael S.

AU - Rose, Beth

AU - Wang, Yibin

PY - 2011/10

Y1 - 2011/10

N2 - The p38 mitogen-activated protein kinases (p38s) are stress-activated Ser/Thr kinases. Their activation has been associated with various pathological stressors in the heart. Activated p38 is implicated in a wide spectrum of cardiac pathologies, including hypertrophy, myocardial infarction, as well as systolic and diastolic heart failure. In this review, the specific contribution of different isoforms of p38 kinases to cardiac diseases as well as TAB-1-mediated non-canonical activation pathway are discussed as a rationale for inhibiting p38 activity to treat cardiac hypertrophy, ischemic injury, and heart failure. Finally, a summary of current clinical trials targeting p38 kinases in cardiovascular diseases is provided to highlight the potential promise as well as existing challenges of this therapeutic approach. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure." (C) 2010 Elsevier Ltd. All rights reserved.

AB - The p38 mitogen-activated protein kinases (p38s) are stress-activated Ser/Thr kinases. Their activation has been associated with various pathological stressors in the heart. Activated p38 is implicated in a wide spectrum of cardiac pathologies, including hypertrophy, myocardial infarction, as well as systolic and diastolic heart failure. In this review, the specific contribution of different isoforms of p38 kinases to cardiac diseases as well as TAB-1-mediated non-canonical activation pathway are discussed as a rationale for inhibiting p38 activity to treat cardiac hypertrophy, ischemic injury, and heart failure. Finally, a summary of current clinical trials targeting p38 kinases in cardiovascular diseases is provided to highlight the potential promise as well as existing challenges of this therapeutic approach. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure." (C) 2010 Elsevier Ltd. All rights reserved.

U2 - 10.1016/j.yjmcc.2010.10.021

DO - 10.1016/j.yjmcc.2010.10.021

M3 - Literature review

SN - 1095-8584

VL - 51

SP - 485

EP - 490

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

IS - 4

ER -

The p38 mitogen-activated protein kinase pathway-A potential target for intervention in infarction, hypertrophy, and heart failure

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this